Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings - Fast Company

Submitted by Anonymous (not verified) on Wed, 01/22/2025 - 17:39

Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings  Fast Company